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Abstract
Background: Anthracyclines are highly effective anticancer medication prescribed for the treatment of breast
cancer. Nevertheless, the use of anthracyclines as chemotherapeutic agents involves a risk for development of
cardiac toxicity which may cause restrictive and dilated cardiomyopathy. Currently, genetic predisposition is not
considered as a risk factor for cardiotoxicity associated to the use of anthracyclines.
Case presentation: We report the case of a 37-years old Panamanian female patient diagnosed with breast cancer who
developed clinical signs of severe heart failure after treatment with doxorubicin. A diagnosis of anthracycline induced
cardiomyopathy was made and treatment was initiated accordingly. A whole exome sequencing study performed to the
patient showed the presence of a missense mutation in LMNA gene, which codifies for lamin A/C. Our results points to a
correlation between the LMNA variant and the anthracycline cardiotoxicity developed by the woman. Improvement of
the clinical symptoms and the left ventricle ejection fraction was observed after proper treatment.
Conclusions: This case report suggests for the first time a potential genetic predisposition for anthracyclines induced
cardiomyopathy in patients with mutations in LMNA gene. Perhaps chemotherapies accelerate or deliver the “second-hit”
in the development of DCM in patients with genetic mutations. More data is needed to understand the contribution of
LMNA variants that predispose to DCM in patients receiving cardiotoxic therapies.
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Background
Anthracyclines, such as doxorubicin and epirubicin, are
highly effective and frequently used antineoplastic drugs pre-
scribed for a variety of malignancies, including breast cancer
[1, 2]. These drugs inhibit the enzyme topoisomerase II, lead-
ing to disruption in DNA replication and transcription,
which in turn impedes multiplication of cancer cells.
Furthermore, they promote the production of Reactive
Oxygen Species (ROS) which damage proteins, DNA and
cell membranes of the fastest-dividing human cancer cells
[2]. Anthracycline-based chemotherapy for the treatment of
breast cancer is very effective, reducing the annual mortality
in women with breast cancer by 20–38%; nevertheless, the
increased risk of cardiotoxicity in patients from anthracycline
use has been very well described and analyzed in the medical
literature [1–3]. The use of anthracyclines as chemothera-
peutic agents involves an evident risk for development of
cardiac toxicity generating restrictive and dilated cardiomy-
opathy resulting in congestive heart failure in approximately
16–20% of the treated patients [4]. The current assumptions
indicate that anthracycline-induced cardiomyopathy is the
result of complex multifactorial processes affecting cardio-
myocytes such as inhibition of protein and nucleic acid
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synthesis, the generation of ROS, through interactions with
topoisomerase-IIβ present in cardiomyocytes, changes in
adrenergic function and adenylate cyclase, increased mem-
brane lipid peroxidation, abnormalities in calcium ion hand-
ling, impairment of membrane binding, enzymatic activity
and assembly of mitochondrial creatine kinase, induction of
nitric oxide synthase enzyme, leading to nitric oxide and per-
oxynitrite and converse nitration/inactivation of myofibrillar
creatine kinase or nitration/activation of metalloproteinases,
accumulation of anthracyclines metabolites in the cardio-
myocytes, and the development of apoptosis [2, 5]. The main
potential risk factors described for anthracycline-induced
cardiotoxicity includes cumulative and individual anthracy-
clines dose, age extremes, female sex, previous history of car-
diovascular disease, pulmonary disease, pregnancy, infection,
reduced infusion time, concomitant radiation therapy, and
concomitant cardiotoxic chemotherapies (e.g her-2 anatgo-
nists) [2]. The damage upon the heart may occur months or
years after chemotherapeutic treatment at or near usual
maximum doses [2, 6, 7]. Although genome-wide association
investigations performed have discovered correlations be-
tween anthracycline cardiotoxicity and specific genetic
mutations, there is not currently enough evidence to recom-
mend screening patients for variants to guide clinical
decision-making for cancer patients.
Here we report the case of a breast cancer patient
with a mutation in LMNA gene who developed
dilated cardiomyopathy (DCM) after treatment with doxo-
rubicin, suggesting a potential genetic predisposition for
DCM in patients with mutations in this gene. As for as
our knowledge, this is the first report that correlates muta-
tions in LMNA as a risk factor for the development of
anthracycline-induced cardiomyopathy.
Case presentation
A 37-year-old Panamanian female patient without a pre-
existing medical history, was diagnosed with a stage IIIB
mammary ductal carcinoma (cT4N0M0), positive estrogen
receptors (ER-positive), negative progesterone receptors
(PR-negative) in her right breast in 2013, for which she
received four cycles of doxorubicin (cumulative dose
240 mg/m2) and cyclophosphamide from January to
March 2013, followed by paclitaxel from April to June. An
electrocardiogram (Fig. 1) and chest radiography done
Fig. 1 Progressive changes observed on electrocardiograms obtained from the proband. The first electrocardiogram (ECG) obtained 6months
after the beginning of the chemotherapy reported inactivable electrical zones at V1 and V3 leads with a cardiac axis of − 17°(a). The proband
presented clinical signs of heart failure 48months after treatment, an ECG at the time reported left anterior hemiblock and signs compatible with
left cavities enlargement, cardiac axis − 46°(b
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prior to chemotherapy revealed no cardiac alterations. In
July 2013 the patient underwent mastectomy, with subse-
quent radiation therapy (45 Gy in 25 fractions).
Two years later, she was admitted to the hospital
emergency department with 10 days history of orthop-
nea, swelling of her arms and legs, bendopnea, and fa-
tigue. An echocardiogram was ordered, showing a
reduced left ventricular systolic function (LVEF 25%).
The diagnosis of anthracyclines induced cardiomyopathy
was established. She was treated with a beta-blocker, di-
uretics and antihypertensives. After two weeks, she
showed a significant improvement of her symptoms,
with a LVEF of 45%. A year later, her 38-year-old brother
was admitted to the hospital with a clinical presentation
characterized by swelling of his legs, fatigue and mini-
mum effort dyspnea, a left ventricular internal diameter
in diastole (LVIDd) of 7.52 cm, with a LVEF of 20%. This
clinical event prompted us to consider whether our pa-
tient had a genetic predisposition for DCM, and thus we
performed a complete pedigree analysis of the proband
(Fig. 2 and Additional file 1: Figure S1) that showed the
presence of several DCM cases in the family.
In order to establish the genetic mutation responsible
for the familial DCM, genomic DNA was extracted from
whole-blood samples of the proband, and her brother,
using a Masterpure DNA purification kit following the
manufacturer’s protocol, and untargeted whole exome
sequencing (WES) assessment was performed. Briefly,
DNA samples were amplified prior to exome library
preparation by means of GenomiPhi V3 DNA Amplifica-
tion Kit. Exome libraries of the selected individuals were
prepared from amplified DNA using an Illumina Nextera
Rapid Capture Exome kit (version 1.1, 37Mb). Genomic
DNA was then tagmented, and amplified using polymerase
chain reaction amplification (PCR); regions of interest
(exons) were captured by hybridization to specific probes
followed by a cycle of PCR amplification. The sequencing
step was performed on an Illumina HiSeq 2500 platform,
targeting for 100 bp pair-end reads, and a mean sequencing
coverage average above 80x. The clinically relevant variant
was subsequently confirmed by means of Sanger sequen-
cing. The genetic investigations revealed the presence of a
LMNA-p.Arg190Trp (NM_170707.3:c.568C >T) missense
variant.
Discussion and conclusions
We present the case of a patient with breast cancer with a
mutation in the LMNA gene who developed cardiomyopathy
after treatment with anthracycline. LMNA codifies for lamin
A/C protein, which has a diversity of roles in the body, such
as nuclear structure support, cell signaling pathway medi-
ation, chromatin organization and DNA repair. Mutations in
LMNA have been associated with the development of variety
of pathologies such as LMNA cardiomyopathy [8, 9].
Variants in LMNA gene are responsible for around 6–8% of
the reported cases of fDCM with conduction-system disease
[10, 11]. The LMNA variant identified in the proband,
LMNA-p.Arg190Trp (NM_170707.3:c.568C >T) which al-
ters the helical rod domain of the protein, has been described
earlier and implicated in acute types of familial DCM with,
and without, conduction-system disease [12–16]. Previous
case series have been reported on patients who developed
anthracycline cardiomyopathy and were subsequently found
to have genetic mutations known to be associated with
DCM, such asMYH7 (β-myosin heavy chain) and TTN (titin
striated muscle protein) [17, 18]. To our knowledge, this is
the first case report of a patient with anthracycline-induced
cardiotioxicity because of a LMNA gene mutation. Despite
Fig. 2 Pedigree of the proband. A summarized pedigree of the proband family is shown. Individuals are numbered according to the generation
and position to which they belong. The proband (V-24) is marked by an arrow. Genomic analysis was performed in all the individuals marked
with an asterisk. Circle: female; square: male; deceased individuals are marked with an X
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the explosion of targeted chemotherapies and immunother-
apies, the use of anthracyclines remains common as they are
highly effective chemotherapies for many different types of
cancers that afflict both adults and children [2, 18, 19]. As
shown in our case, for cancer patients bearing the mutation
highlighted in LMNA gene, treatment with anthracyclines
can be considered a risk factor for cardiotoxicity and early
development of dilated cardiomyopathy due to their genetic
predisposition. More data is needed to understand the con-
tribution and frequency of mutations (such as LMNA) that
predispose to DCM in patients receiving potentially cardio-
toxic therapies such as anthracyclines. While penetrance is
incomplete in DCM genes, perhaps chemotherapies acceler-
ate or deliver the “second-hit” in the development of DCM
in patients with genetic mutations. One can envision, if fur-
ther evidence supports this hypothesis, that we could truly
offer precision medicine by screening patients prior to start-
ing chemotherapy for genetic mutations that would increase
their risk of developing heart failure.
Additional file
Additional file 1: Figure S1. Support Information. Complete Pedigree
of the proband family. Displays the complete pedigree of the proband
family. Individuals are numbered according to the generation and
position to which they belong. The distribution of the cases suggest the
presence of an autosomal dominant disease. Circle: female; square: male;
deceased individuals are marked with an X. (JPG 514 kb)
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